动物来源放线菌的次级代谢产物及其生物活性研究进展
发布时间：2018-09-09 09:08
【摘要】：放线菌是抗生素的主要来源之一,在人类对抗由致病菌产生的感染性疾病的过程中发挥了不可替代的防治作用。近年来,由于耐药菌株的不断涌现,促使人们加快寻找新的抗生素的步伐。寄生于动物体内的共生放线菌,是目前药用微生物资源的一个重要来源,也是当前微生物药物研究领域的一个热点。这些微生物在与动物互生共存的演化过程中,组成了一个动物-细菌共同体,进而构建成为一个协调而相对独立的微生态环境。在这一特殊环境中,放线菌所产生的次级代谢产物,既可被动物机体所耐受,又具有抑制特定病原微生物的活性。这类次级代谢产物种类繁多、结构特异,具有抗细菌、真菌、病毒、肿瘤及免疫调节等多种生物活性,具备开发成为新型药物的巨大潜力。本文旨在总结近十年来关于动物来源放线菌的次级代谢产物及其生物学活性的研究进展,为进一步开发新型药物提供参考和研究策略。
[Abstract]:Actinomycetes, one of the main sources of antibiotics, plays an irreplaceable role in the prevention and treatment of infectious diseases caused by pathogenic bacteria. In recent years, due to the emergence of drug-resistant strains, people speed up the search for new antibiotics. Symbiotic actinomycetes parasitic on animals is an important source of medicinal microbial resources and a hot spot in the field of microbial drug research. In the evolution process of co-existence of these microorganisms with animals, they formed an animal-bacterial community, and then formed a coordinated and relatively independent microecological environment. In this special environment, the secondary metabolites produced by actinomycetes can be tolerated by animals and have the activity of inhibiting specific pathogenic microorganisms. This kind of secondary metabolites have a variety of species, specific structure, anti-bacterial, fungal, virus, tumor and immune regulation and other biological activities, has a great potential to develop as a new drug. The purpose of this paper is to summarize the research progress on secondary metabolites and their biological activities of actinomycetes from animal origin in recent ten years, and to provide references and research strategies for the further development of new drugs.
【作者单位】： 南方医科大学药学院;中国医学科学院北京协和医学院药物研究所;
【基金】：广东省科技厅资助项目(2014A020210014,2015A020211010)
【分类号】：R915
[Abstract]:Actinomycetes, one of the main sources of antibiotics, plays an irreplaceable role in the prevention and treatment of infectious diseases caused by pathogenic bacteria. In recent years, due to the emergence of drug-resistant strains, people speed up the search for new antibiotics. Symbiotic actinomycetes parasitic on animals is an important source of medicinal microbial resources and a hot spot in the field of microbial drug research. In the evolution process of co-existence of these microorganisms with animals, they formed an animal-bacterial community, and then formed a coordinated and relatively independent microecological environment. In this special environment, the secondary metabolites produced by actinomycetes can be tolerated by animals and have the activity of inhibiting specific pathogenic microorganisms. This kind of secondary metabolites have a variety of species, specific structure, anti-bacterial, fungal, virus, tumor and immune regulation and other biological activities, has a great potential to develop as a new drug. The purpose of this paper is to summarize the research progress on secondary metabolites and their biological activities of actinomycetes from animal origin in recent ten years, and to provide references and research strategies for the further development of new drugs.
【作者单位】： 南方医科大学药学院;中国医学科学院北京协和医学院药物研究所;
【基金】：广东省科技厅资助项目(2014A020210014,2015A020211010)
【分类号】：R915
【相似文献】
相关期刊论文 前10条
1 杨烨;王e，
本文编号：2231940
本文链接：https://www.wllwen.com/yixuelunwen/yiyaoxuelunwen/2231940.html
最近更新
教材专著
